- Home
- CRSP vs BCC Comparison
CRSP vs BCC Comparison
Compare CRSP & BCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- BCC
- Stock Information
- Founded
- CRSP 2013
- BCC 2004
- Country
- CRSP Switzerland
- BCC United States
- Employees
- CRSP N/A
- BCC N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- BCC RETAIL: Building Materials
- Sector
- CRSP Health Care
- BCC Consumer Discretionary
- Exchange
- CRSP Nasdaq
- BCC Nasdaq
- Market Cap
- CRSP 4.1B
- BCC 5.3B
- IPO Year
- CRSP 2016
- BCC 2013
- Fundamental
- Price
- CRSP $44.62
- BCC $124.20
- Analyst Decision
- CRSP Buy
- BCC Buy
- Analyst Count
- CRSP 19
- BCC 3
- Target Price
- CRSP $74.38
- BCC $129.33
- AVG Volume (30 Days)
- CRSP 989.9K
- BCC 252.4K
- Earning Date
- CRSP 08-05-2024
- BCC 10-28-2024
- Dividend Yield
- CRSP N/A
- BCC 0.31%
- EPS Growth
- CRSP N/A
- BCC N/A
- EPS
- CRSP N/A
- BCC 11.46
- Revenue
- CRSP $202,227,000.00
- BCC $6,921,787,000.00
- Revenue This Year
- CRSP N/A
- BCC N/A
- Revenue Next Year
- CRSP $461.06
- BCC $5.50
- P/E Ratio
- CRSP N/A
- BCC $10.83
- Revenue Growth
- CRSP 18.89
- BCC N/A
- 52 Week Low
- CRSP $37.55
- BCC $87.32
- 52 Week High
- CRSP $91.10
- BCC $154.67
- Technical
- Relative Strength Index (RSI)
- CRSP 35.02
- BCC 42.57
- Support Level
- CRSP $46.86
- BCC $122.62
- Resistance Level
- CRSP $48.27
- BCC $126.56
- Average True Range (ATR)
- CRSP 1.80
- BCC 4.08
- MACD
- CRSP -0.11
- BCC -1.00
- Stochastic Oscillator
- CRSP 16.42
- BCC 8.76
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.
About BCC Boise Cascade L.L.C.
Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two segments namely Wood Products and Building Materials Distribution. Wood Products segment manufactures EWP, consisting of laminated veneer lumber (LVL), I-joists, and laminated beams. The Building Materials Distribution segment is engaged in the wholesale of building materials. It distributes products such as plywood, OSB, and lumber items such as siding, doors, metal products, insulation, and roofing, EWP and others. The company generates a majority of its revenue from the Building Material Distribution segment.